Enrolling by invitationPhase 2NCT07393373
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Studying Hypochondroplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- QED Therapeutics, a BridgeBio company
- Principal Investigator
- QED Therapeutics SVP, Clinical DevelopmentQED Therapeutics, a BridgeBio company
- Intervention
- Infigratinib(drug)
- Enrollment
- 135 enrolled
- Eligibility
- 3-18 years · All sexes
- Timeline
- 2026 – 2036
Study locations (25)
- UCSF Benioff Children's Hospital, Oakland, California, United States
- Childrens Hospital Colorado, Aurora, Colorado, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- University of Missouri, Columbia, Missouri, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic, Madison, Wisconsin, United States
- Murdoch Children's Research Institute, Parkville, Victoria, Australia
- London Health Sciences Centre - Children's Hospital of Western Ontario, London, Ontario, Canada
- Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
- Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada
- Hôpital Femme Mère Enfant, Bron, France
- Hôpital Universitaire Necker-Enfants Malades, Paris, France
- Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants, Toulouse, France
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07393373 on ClinicalTrials.govOther trials for Hypochondroplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07126262A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsBioMarin Pharmaceutical
- ENROLLING BY INVITATIONPHASE3NCT07073014Long-Term Extension Study of Vosoritide to Treat Children With HypochondroplasiaBioMarin Pharmaceutical
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT06873035An Interventional Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- ACTIVE NOT RECRUITINGPHASE3NCT06455059Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaBioMarin Pharmaceutical
- RECRUITINGNCT06410976Prospective Clinical Assessment Study in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- RECRUITINGNCT06212947A Multicenter Multinational Observational Study of Children With HypochondroplasiaBioMarin Pharmaceutical